Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors.

Malavige, GN; Jones, L; Black, AP; Ogg, GS

Abstract:

Varicella zoster viru (VZV)-specific T cell responses are believed to be vital in recovery from primary VZV infection and also in the prevention of viral reactivation. While glycoprotein E (gE) is the most abundant and one of the most immunogenic proteins of the virus, there are no data addressing potential T cell epitopes within gE, nor the phenotype of specific T cells. Using interferon gamma enzyme-linked immunospot assays and intracellular cytokine assays, we identified gE-specific immune...

Expand abstract

Publication status:

Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Malavige, G. N., Jones, L., Black, A. P., & Ogg, G. S. (2008). Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clinical and Experimental Immunology, 152(3), 522–531.

MLA Style

Malavige, G. N., et al. “Varicella Zoster Virus Glycoprotein E-Specific CD4+ T Cells Show Evidence of Recent Activation and Effector Differentiation, Consistent with Frequent Exposure to Replicative Cycle Antigens in Healthy Immune Donors.” Clinical and Experimental Immunology, vol. 152, no. 3, Clinical and experimental immunology, 2008, pp. 522–31.

Chicago Style

Malavige, GN, L Jones, AP Black, and GS Ogg. 2008. “Varicella Zoster Virus Glycoprotein E-Specific CD4+ T Cells Show Evidence of Recent Activation and Effector Differentiation, Consistent with Frequent Exposure to Replicative Cycle Antigens in Healthy Immune Donors.” Clinical and Experimental Immunology 152 (3): 522–31.
Tweet
Print